Solventum Corporation (NYSE:SOLV) Receives $88.64 Consensus Price Target from Analysts

Shares of Solventum Corporation (NYSE:SOLV) have been assigned an average recommendation of “Hold” from the fourteen analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $90.2727.

A number of equities analysts recently weighed in on SOLV shares. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Tuesday, December 2nd. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Finally, UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st.

Solventum Stock Performance

Shares of NYSE SOLV opened at $80.28 on Tuesday. The company’s fifty day moving average price is $81.58 and its 200 day moving average price is $75.69. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The company has a market capitalization of $13.92 billion, a PE ratio of 9.25, a price-to-earnings-growth ratio of 7.35 and a beta of 0.34. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter in the previous year, the company earned $1.64 earnings per share. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, research analysts predict that Solventum will post 6.58 earnings per share for the current year.

Solventum announced that its Board of Directors has initiated a stock buyback plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 7.5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SOLV. Massachusetts Financial Services Co. MA boosted its holdings in Solventum by 19.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 20,425 shares of the company’s stock worth $1,618,000 after buying an additional 3,279 shares during the last quarter. Apollon Wealth Management LLC boosted its position in Solventum by 10.1% during the fourth quarter. Apollon Wealth Management LLC now owns 3,865 shares of the company’s stock worth $306,000 after acquiring an additional 355 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in Solventum during the 4th quarter valued at about $414,000. Oak Thistle LLC acquired a new stake in Solventum in the 4th quarter valued at about $2,447,000. Finally, QV Investors Inc. lifted its stake in Solventum by 1.8% in the 4th quarter. QV Investors Inc. now owns 239,252 shares of the company’s stock worth $18,958,000 after purchasing an additional 4,170 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.